Investigation of the antineoplastic effect of miRNA-181a and development a novel pharmaceutical approaches for treating advanced retinoblastoma

研究 miRNA-181a 的抗肿瘤作用并开发治疗晚期视网膜母细胞瘤的新药物方法

• 批准号: 408449
• 负责人: Hardy Pierre
• 金额: $ 46.81万
• 依托单位: Centre hospitalier universitaire Sainte-Justine (Montral, Qubec)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-09-01 至 2024-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=408449&lang=en
• 关键词: Anti-Tumor Effects; Cell Survival Signaling Pathway; Csl3 Liposome; Intravitreal Injection; Melphalan; Microrna-181a; Nanoparticle-Based Techniques; Retinoblastoma; Spleen Tyrosine Kinase (Syk); Vitreous Seeds

Retinoblastoma (Rb) is the most common cancer of the eye in children and accounts for 3% of all childhood malignancies. Yet, despite considerable efforts, persistent or recurrent tumor growing in vitreous cavity is still a major cause of treatment failure

视网膜母细胞瘤(RB)是儿童最常见的眼癌，占所有儿童恶性肿瘤的3%。然而，尽管作出了相当大的努力，玻璃体腔内持续或复发的肿瘤仍然是治疗失败的主要原因。